In summary, this work provides the first evidence that PA exerts anti-NSCLC effects by targeting the GNAI1/ARRB1 axis, offering a promising therapeutic strategy against advanced NSCLC. This evidence concerns the gene GNAI1 and non-small cell lung carcinoma.